arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Apogee Therapeutics, Inc.

APGE

$134.83 ▲ +0.32 (+0.24%) at close

4 Visible periods

14 Metrics

Absolute Benchmarks

Price Chart

Health

Weak

Bearish Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, Apogee Therapeutics, Inc. shows weak fundamentals, weighed down by FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $8.2B

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC —

FCF / Share $-3.83 ↘

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

4-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-255.84M

↓ -40.5% —

FCF / Share Free cash flow per share

$-3.83

↓ -22.8% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

FCF / Net IncomeFCF / Net Income of 0.91x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
EPS Growth YoY (%)	-27.9% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	1.8% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	79.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—
Net Income Growth YoY (%)	-40.5% Weak ↑ Weak Improving Year-over-year change in net income	-116.9% Weak Weak Year-over-year change in net income	-111.1% Weak Weak Year-over-year change in net income	—
FCF Growth YoY (%)	-22.8% Weak ↓ Weak Declining Year-over-year change in free cash flow	-4.2% Weak Weak Year-over-year change in free cash flow	55.1% Excellent Excellent Year-over-year change in free cash flow	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Effective Tax Rate (%) (%)	-0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
FCF / Net Income (x)	0.91x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.41x Weak Weak Free cash flow relative to reported net income Optimal: > 1x

🎯 Is capital allocation efficient? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Return on Capital (%) (%)	-30.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-28.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-23.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-20.2% Weak Weak Operating profit relative to total assets Optimal: > 10%

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Net Debt (USD)	$-131.55M	$-141.79M	$-118.32M	$-151.89M

📊 What does each share earn? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Basic EPS, GAAP (USD)	$-4.22	$-3.30	$-3.36	$-16.16
Free Cash Flow per Share (USD)	$-3.83	$-3.12	$-3.00	$-6.67
Basic Weighted Avg Shares (shares)	60.69M	55.19M	25.01M	2.46M

🏦 How resilient is the balance sheet? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$713.45M	$501.15M	$377.85M	$142.07M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Depreciation Expense (USD)	$1.42M	$189.00K	—	—
Net Income, GAAP (USD)	$-255.84M	$-182.15M	$-83.98M	$-39.78M
Operating Cash Flow (USD)	$-227.45M	$-171.17M	$-74.76M	$-16.43M

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 16 quarters

Apogee Therapeutics, Inc.

Analytical Summary

4-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare APGE with peers